Filtros : "DIABETES MELLITUS" "Amarin" Limpar

Filtros



Refine with date range


  • Source: Circulation. Unidade: FM

    Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 14 maio 2024.
    • APA

      Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
    • NLM

      Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 maio 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
    • Vancouver

      Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 maio 14 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024